

DOCUMENT INFO

Name: Shell Meeting - April 9, 2001.ppt

Location: Z:\Shanghai\Shell's position\

Size: 87KB (88,064 bytes)

Modified: Monday, April 9, 2001 3:29 PM

Comments: PowerPoint could not open the file. (ErrCode=-2147467259, Line=80, ProcName=Microsoft Office PowerPoint 2007)

DOCUMENT INFO

DRAFT

Shanghai Health Study – Shell Discussion of Options

Background: There has been a request for additional funding for the Shanghai Health Study. The current approved and funded budget is \$26.4MM; the request for additional funding is approximately \$10.1 MM. Shell's share would be \$2MM.

The 10.1 can be broken down into 3 components:

Irons (U of Colorado)	7.4
Lab Transition	1.2
Other contracts	1.5

Options range from no additional funding to fully funding request. An analysis of benefits/regrets:

Options	No additional \$	Fund smaller scope	Fund max \$	Fund max \$ w/ definite end date	Finish Study	Fund lab transition
RECOMMENDATION						
Description of Option	When current funding runs out, analyze data collected and publish	Fund CC to x cases and ME directed @ lymphocytic effects	Agree a max increase	Agree a max increase with a firm end date	Fund request with goal to finish protocols	Fund lab for continued diagnostics while new funds are identified
Benefits	Large case control cohort for AML/NHL, but short of protocols (500)	Larger cohort for AML/NHL.	Larger cohort for AML/NHL.	Larger cohort for AML/NHL.	500 AML/NHL cohort for evaluating effects of benzene exposure Get relative risk for AML/NHL	
	Benzene-induced MDS identified at high exposures	ME most beneficial data	ME most beneficial data	ME most beneficial data	ME: Potential for better understanding of biomarkers of exposure & effects	
	Nutritional anemias incorrectly diagnosed as AML				More time for disease progression follow-up	
Advanced the science in hematopoietic disease diagnosis						

Options	No additional \$	Fund smaller scope	Fund max \$	Fund max \$ w/ definite end date	Finish Study	Fund lab transition
Regrets	Do not finish study				May not achieve full protocol expectations	
	Large investment for small return	Larger investment for a little more data				
	NHL ? not answered	May answer NHL question			May answer NHL question	
	No dose response curve or threshold				May not get dose response curve or threshold	

Other Considerations:

1. Contract between Shell and API
 - Leave prior to completion – liable for share of full cost
 - Could change the scope, per Article 7, appendix A
 - Consortium can terminate work, per Article 6
 - Put an absolute \$ cap
 - Shell could agree to a “buy-out” of its share; i.e. Shell agrees to pay an additional amount and consortium agrees
2. Reputation

Proposed changes that could be made:

1. Project management
2. QA/QC function increased
3. Grant with University of Colorado changed to a contract
4. Sponsors Executive Briefing by investigator

Shell Next Steps:

1. Understand potential reputation impact
2. Brief key people in Chemicals
3. Develop Shell starting position with boundaries for upcoming consortium meeting
4. Engage with Shell outside Chemicals